Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma – guidance (TA661)

Pembrolizumab is recommended for untreated metastatic/unresectable recurrent head and neck squamous cell carcinoma in adults with PD‑L1+ve tumours with a combined positive score of 1 or more; only if given as monotherapy, and stopped after a max 2 years uninterrupted treatment.

National Institute for Health and Care Excellence